- 著者
-
Yugo Yamashita
Yuuki Maruyama
Hirono Satokawa
Yuji Nishimoto
Ichizo Tsujino
Hideki Sakashita
Hiroko Nakata
Yoshinori Okuno
Yoshito Ogihara
Sen Yachi
Naoki Toya
Masami Shingaki
Satoshi Ikeda
Naoto Yamamoto
Shizu Aikawa
Nobutaka Ikeda
Hiroya Hayashi
Shingo Ishiguro
Eriko Iwata
Michihisa Umetsu
Akane Kondo
Takehisa Iwai
Takao Kobayashi
Makoto Mo
Norikazu Yamada
on behalf of the Taskforce of VTE and COVID-19 in Japan Study
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-21-0169, (Released:2021-05-20)
- 参考文献数
- 33
- 被引用文献数
-
30
Background:Coronavirus disease 2019 (COVID-19) reportedly causes venous thromboembolism (VTE), but the status of this complication in Japan was unclear.Methods and Results:The VTE and COVID-19 in Japan Study is a retrospective, multicenter cohort study enrolling hospitalized patients with COVID-19 who were evaluated with contrast-enhanced computed tomography (CT) examination at 22 centers in Japan between March 2020 and October 2020. Among 1,236 patients with COVID-19, 45 (3.6%) were evaluated with contrast-enhanced CT examination. VTE events occurred in 10 patients (22.2%), and the incidence of VTE in mild, moderate, and severe COVID-19 was 0%, 11.8%, and 40.0%, respectively. COVID-19 patients with VTE showed a higher body weight (81.6 vs. 64.0 kg, P=0.005) and body mass index (26.9 vs. 23.2 kg/m2, P=0.04), and a higher proportion had a severe status for COVID-19 compared with those without. There was no significant difference in the proportion of patients alive at discharge between patients with and without VTE (80.0% vs. 88.6%, P=0.48). Among 8 pulmonary embolism (PE) patients, all were low-risk PE.Conclusions:Among a relatively small number of patients undergoing contrast-enhanced CT examination in Japanese real-world clinical practice, there were no VTE patients among those with mild COVID-19, but the incidence of VTE seemed to be relatively high among severe COVID-19 patients, although all PE events were low-risk without significant effect on mortality risk.